Drug Profile
Solifenacin succinate - Hanmi Pharmaceutical
Alternative Names: HGP-1103Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Esters; Irritable bowel syndrome therapies; Isoquinolines; Quinuclidines; Small molecules; Urologics
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Overactive bladder(In volunteers) in South Korea (PO)
- 16 Nov 2016 Chemical structure information added
- 01 May 2016 Hanmi Pharmaceutical completes a phase I trial in Overactive bladder (In volunteers) in South Korea (PO) (NCT02940314)